Please enable JavaScript to continue using this application.

Compare $CUE vs $RNAC | Chartloom

Compare

$CUE vs $RNAC

Cue Biopharma Inc · Cartesian Therapeutics Inc

CUE

Cue Biopharma Inc

RNAC

Cartesian Therapeutics Inc

Compare $CUE vs $RNAC

Comparing Cue Biopharma Inc and Cartesian Therapeutics Inc

CUECue Biopharma Inc

RNACCartesian Therapeutics Inc

CUECue Biopharma Inc

Market cap

$112M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

354.4%

YTD performance

173.6%

52W performance

7.5%

FCF yield

-44.8%

RNACCartesian Therapeutics Inc

Market cap

$207M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

473.62x

Rev growth (TTM)

-20.7%

YTD performance

4.4%

52W performance

-31.0%

FCF yield

-37.9%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

CUE

RNAC

Detailed metrics comparison

CUE

Cue Biopharma Inc

RNAC

Cartesian Therapeutics Inc

Market Cap

CUE$112M

RNAC$207M

Enterprise Value

CUE$95M

RNAC$113M

Price

CUE$27.66

RNAC$7.06

P/E Ratio

CUEN/A

RNACN/A

P/S Ratio

CUE2.98x

RNAC140.34x

EV/Sales

CUE2.51x

RNAC76.18x

EV/EBITDA

CUE0.00x

RNAC0.00x

P/B Ratio

CUE80.41x

RNAC296.12x

P/FCF Ratio

CUEN/A

RNACN/A

EV/FCF

CUE-1.89x

RNAC-1.43x

PEG Ratio

CUEN/A

RNACN/A

Forward P/E (NTM)

CUEN/A

RNACN/A

Forward P/S (NTM)

CUEN/A

RNAC473.62x

Revenue (TTM)

CUE$38M

RNAC$1M

Revenue Growth (YoY)

CUE354.4%

RNAC-20.7%

Forward Rev Growth

CUE-38.2%

RNAC-14.0%

Gross Margin (TTM)

CUE0.0%

RNAC0.0%

Operating Margin (TTM)

CUE0.0%

RNAC0.0%

EBITDA Margin (TTM)

CUE-258.4%

RNAC-6503.1%

Net Margin (TTM)

CUE-435.8%

RNAC-10422.5%

FCF Margin (TTM)

CUE-133.2%

RNAC-5322.4%

Net Income (TTM)

CUE$-164M

RNAC$-154M

FCF (TTM)

CUE$-50M

RNAC$-79M

EPS (TTM)

CUE-$25.88

RNAC-$5.16

ROE (TTM)

CUE-103219.0%

RNAC-321582.0%

ROA (TTM)

CUE-48467.0%

RNAC-4761.0%

ROIC (TTM)

CUE-100612.0%

RNAC-321582.0%

Cash

CUE$17M

RNAC$148M

Debt

CUE$0

RNAC$53M

Net Cash/Debt

CUE$17M

RNAC$95M

Current Ratio (TTM)

CUE1.25x

RNAC7.48x

Quick Ratio (TTM)

CUE1.16x

RNAC7.19x

Debt/Equity (TTM)

CUE0.00x

RNAC0.28x

Debt/Assets (TTM)

CUE0.0%

RNAC0.0%

Interest Coverage (TTM)

CUEN/A

RNACN/A

Net Debt/EBITDA (TTM)

CUE0.00x

RNAC0.00x

Beta

CUE2.84

RNAC0.74

52W Performance

CUE7.5%

RNAC-31.0%

YTD Performance

CUE173.6%

RNAC4.4%

% from 52W High

CUE-39.2%

RNAC-35.9%

% from 52W Low

CUE456.4%

RNAC26.0%

Asset Turnover (TTM)

CUE1.11x

RNAC0.01x

FCF Yield (TTM)

CUE-44.8%

RNAC-37.9%

Earnings Yield (TTM)

CUE-146.5%

RNAC-74.3%

Dividend Yield (TTM)

CUEN/A

RNACN/A

Rule of 40

CUE221.1

RNAC-5,343.1

EV/GP/RG

CUEN/A

RNACN/A

Ticker research

View CUE research View RNAC research

Metric	CUE Cue Biopharma Inc	RNAC Cartesian Therapeutics Inc
Market & Valuation
Market Cap	$112M	$207M
Enterprise Value	$95M	$113M
Price	$27.66	$7.06
P/E Ratio	N/A	N/A
P/S Ratio	2.98x	140.34x
EV/Sales	2.51x	76.18x
EV/EBITDA	0.00x	0.00x
P/B Ratio	80.41x	296.12x
P/FCF Ratio	N/A	N/A
EV/FCF	-1.89x	-1.43x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	473.62x
Revenue & Growth
Revenue (TTM)	$38M	$1M
Revenue Growth (YoY)	354.4%	-20.7%
Forward Rev Growth	-38.2%	-14.0%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-258.4%	-6503.1%
Net Margin (TTM)	-435.8%	-10422.5%
FCF Margin (TTM)	-133.2%	-5322.4%
Net Income (TTM)	$-164M	$-154M
FCF (TTM)	$-50M	$-79M
EPS (TTM)	-$25.88	-$5.16
ROE (TTM)	-103219.0%	-321582.0%
ROA (TTM)	-48467.0%	-4761.0%
ROIC (TTM)	-100612.0%	-321582.0%
Financial Health
Cash	$17M	$148M
Debt	$0	$53M
Net Cash/Debt	$17M	$95M
Current Ratio (TTM)	1.25x	7.48x
Quick Ratio (TTM)	1.16x	7.19x
Debt/Equity (TTM)	0.00x	0.28x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.84	0.74
52W Performance	7.5%	-31.0%
YTD Performance	173.6%	4.4%
% from 52W High	-39.2%	-35.9%
% from 52W Low	456.4%	26.0%
Efficiency & Yields
Asset Turnover (TTM)	1.11x	0.01x
FCF Yield (TTM)	-44.8%	-37.9%
Earnings Yield (TTM)	-146.5%	-74.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	221.1	-5,343.1
EV/GP/RG	N/A	N/A
Ticker research	View CUE research	View RNAC research

Valuation

P/S Ratio

CUE

2.98x

RNAC

140.34x

EV/FCF

CUE

-1.89x

RNAC

-1.43x

Growth & revenue

Revenue Growth TTM

CUE

354.4%

RNAC

-20.7%

Forward Revenue Growth

RNAC

-14.0%

CUE

-38.2%

Profitability & performance

Gross Margin

CUE

0.0%

RNAC

0.0%

ROE

CUE

-103219.0%

RNAC

-321582.0%

FCF Yield %

RNAC

-37.9%

CUE

-44.8%

52-Week Performance

CUE

7.5%

RNAC

-31.0%

Detailed metrics comparison

CUE

Cue Biopharma Inc

RNAC

Cartesian Therapeutics Inc

Market Cap

CUE$112M

RNAC$207M

Enterprise Value

CUE$95M

RNAC$113M

Price

CUE$27.66

RNAC$7.06

P/E Ratio

CUEN/A

RNACN/A

P/S Ratio

CUE2.98x

RNAC140.34x

EV/Sales

CUE2.51x

RNAC76.18x

EV/EBITDA

CUE0.00x

RNAC0.00x

P/B Ratio

CUE80.41x

RNAC296.12x

P/FCF Ratio

CUEN/A

RNACN/A

EV/FCF

CUE-1.89x

RNAC-1.43x

PEG Ratio

CUEN/A

RNACN/A

Forward P/E (NTM)

CUEN/A

RNACN/A

Forward P/S (NTM)

CUEN/A

RNAC473.62x

Revenue (TTM)

CUE$38M

RNAC$1M

Revenue Growth (YoY)

CUE354.4%

RNAC-20.7%

Forward Rev Growth

CUE-38.2%

RNAC-14.0%

Gross Margin (TTM)

CUE0.0%

RNAC0.0%

Operating Margin (TTM)

CUE0.0%

RNAC0.0%

EBITDA Margin (TTM)

CUE-258.4%

RNAC-6503.1%

Net Margin (TTM)

CUE-435.8%

RNAC-10422.5%

FCF Margin (TTM)

CUE-133.2%

RNAC-5322.4%

Net Income (TTM)

CUE$-164M

RNAC$-154M

FCF (TTM)

CUE$-50M

RNAC$-79M

EPS (TTM)

CUE-$25.88

RNAC-$5.16

ROE (TTM)

CUE-103219.0%

RNAC-321582.0%

ROA (TTM)

CUE-48467.0%

RNAC-4761.0%

ROIC (TTM)

CUE-100612.0%

RNAC-321582.0%

Cash

CUE$17M

RNAC$148M

Debt

CUE$0

RNAC$53M

Net Cash/Debt

CUE$17M

RNAC$95M

Current Ratio (TTM)

CUE1.25x

RNAC7.48x

Quick Ratio (TTM)

CUE1.16x

RNAC7.19x

Debt/Equity (TTM)

CUE0.00x

RNAC0.28x

Debt/Assets (TTM)

CUE0.0%

RNAC0.0%

Interest Coverage (TTM)

CUEN/A

RNACN/A

Net Debt/EBITDA (TTM)

CUE0.00x

RNAC0.00x

Beta

CUE2.84

RNAC0.74

52W Performance

CUE7.5%

RNAC-31.0%

YTD Performance

CUE173.6%

RNAC4.4%

% from 52W High

CUE-39.2%

RNAC-35.9%

% from 52W Low

CUE456.4%

RNAC26.0%

Asset Turnover (TTM)

CUE1.11x

RNAC0.01x

FCF Yield (TTM)

CUE-44.8%

RNAC-37.9%

Earnings Yield (TTM)

CUE-146.5%

RNAC-74.3%

Dividend Yield (TTM)

CUEN/A

RNACN/A

Rule of 40

CUE221.1

RNAC-5,343.1

EV/GP/RG

CUEN/A

RNACN/A

Ticker research

View CUE research View RNAC research

Metric	CUE Cue Biopharma Inc	RNAC Cartesian Therapeutics Inc
Market & Valuation
Market Cap	$112M	$207M
Enterprise Value	$95M	$113M
Price	$27.66	$7.06
P/E Ratio	N/A	N/A
P/S Ratio	2.98x	140.34x
EV/Sales	2.51x	76.18x
EV/EBITDA	0.00x	0.00x
P/B Ratio	80.41x	296.12x
P/FCF Ratio	N/A	N/A
EV/FCF	-1.89x	-1.43x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	473.62x
Revenue & Growth
Revenue (TTM)	$38M	$1M
Revenue Growth (YoY)	354.4%	-20.7%
Forward Rev Growth	-38.2%	-14.0%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-258.4%	-6503.1%
Net Margin (TTM)	-435.8%	-10422.5%
FCF Margin (TTM)	-133.2%	-5322.4%
Net Income (TTM)	$-164M	$-154M
FCF (TTM)	$-50M	$-79M
EPS (TTM)	-$25.88	-$5.16
ROE (TTM)	-103219.0%	-321582.0%
ROA (TTM)	-48467.0%	-4761.0%
ROIC (TTM)	-100612.0%	-321582.0%
Financial Health
Cash	$17M	$148M
Debt	$0	$53M
Net Cash/Debt	$17M	$95M
Current Ratio (TTM)	1.25x	7.48x
Quick Ratio (TTM)	1.16x	7.19x
Debt/Equity (TTM)	0.00x	0.28x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.84	0.74
52W Performance	7.5%	-31.0%
YTD Performance	173.6%	4.4%
% from 52W High	-39.2%	-35.9%
% from 52W Low	456.4%	26.0%
Efficiency & Yields
Asset Turnover (TTM)	1.11x	0.01x
FCF Yield (TTM)	-44.8%	-37.9%
Earnings Yield (TTM)	-146.5%	-74.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	221.1	-5,343.1
EV/GP/RG	N/A	N/A
Ticker research	View CUE research	View RNAC research